Todd Chappell has sold KRRO and made no open-market buys since Jun 2026

Todd Chappell, MBA, is the Chief Operating Officer of Korro Bio, Inc. (NASDAQ: KRRO), an RNA editing therapeutics company, and serves as a corporate insider through his equity ownership and recent stock transactions.( He was promoted to COO from his prior role as Senior Vice President of Strategy and Portfolio Planning as Korro prepared for its reverse merger with Frequency Therapeutics, reflecting his central role in product strategy and execution.( Korro and external announcements note that he brings over 20 years of product development and product strategy experience in the biopharmaceutical sector to the COO position.(

In his current role, Chappell oversees Korro Bio’s operations and contributes to advancing its OPERA RNA editing platform and pipeline, including representing the company at industry conferences such as the RNA Leaders USA Congress.( As an executive officer, he has engaged in equity-based compensation and related transactions, including a June 2026 sale of shares to cover tax withholding obligations associated with restricted stock units granted under Korro Bio’s 2023 Stock Option and Incentive Plan, after which he continued to hold a significant personal stake in the company.( Chappell holds an MBA, underscoring his formal training in business and management alongside his operational and strategic experience in biotech.(

Written by Perplexity from public sources.